The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib https://www.biorxiv.org/content/10.1101/2023.02.10.528011v1?med=mas
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib https://www.biorxiv.org/content/10.1101/2023.02.10.528011v1?med=mas